Source:http://linkedlifedata.com/resource/pubmed/id/20687982
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2010-9-7
|
pubmed:databankReference | |
pubmed:abstractText |
A significant unmet medical need exists in patients with uncontrolled asthma. The purpose of this study was to evaluate the efficacy and safety of mometasone furoate/formoterol (MF/F) 400/10 microg versus MF 400 microg administered twice-daily (b.i.d.) via metered-dose inhaler in patients with asthma uncontrolled on high-dose inhaled corticosteroids (ICS). In a 12-week, randomized, multicenter, double-blind, parallel-group study, patients (>or=12 years of age) were randomized to MF/F 200/10 microg, MF/F 400/10 microg, or MF 400 microg, b.i.d. after a 2- to 3-week open-label run in with MF 400 microg b.i.d. The primary end point was mean change in area under the curve from 0 to 12 hours in forced expiratory volume in 1 second (FEV(1) AUC(0-12h)) from baseline to week 12 for MF/F 400/10 microg versus MF 400 microg. Effects of MF/F on asthma control and symptoms were evaluated and adverse events recorded. Seven hundred twenty-eight patients were randomized. Significant improvement from baseline to week 12 occurred for mean change in FEV(1) AUC(0-12h) with MF/F 400/10 microg (4.19 L x hour) versus MF 400 microg (2.04 L x hour; p < 0.001). Both MF/F doses resulted in rapid (5 minutes) and sustained improvement in lung function throughout 12 weeks. Both MF/F doses were superior to MF in improving asthma control and reducing nocturnal awakenings due to asthma requiring short-acting beta(2)-agonist use. All treatments were well tolerated. Asthma patients who were poorly controlled on high-dose ICS experienced significant improvement in asthma control, lung function, and symptoms when treated with MF/F compared with MF.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenal Cortex Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Bronchodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Ethanolamines,
http://linkedlifedata.com/resource/pubmed/chemical/Pregnadienediols,
http://linkedlifedata.com/resource/pubmed/chemical/formoterol,
http://linkedlifedata.com/resource/pubmed/chemical/mometasone furoate
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1539-6304
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
280-9
|
pubmed:dateRevised |
2011-8-12
|
pubmed:meshHeading |
pubmed-meshheading:20687982-Adrenal Cortex Hormones,
pubmed-meshheading:20687982-Adult,
pubmed-meshheading:20687982-Asthma,
pubmed-meshheading:20687982-Bronchodilator Agents,
pubmed-meshheading:20687982-Clinical Protocols,
pubmed-meshheading:20687982-Disease Progression,
pubmed-meshheading:20687982-Drug Combinations,
pubmed-meshheading:20687982-Ethanolamines,
pubmed-meshheading:20687982-Female,
pubmed-meshheading:20687982-Follow-Up Studies,
pubmed-meshheading:20687982-Humans,
pubmed-meshheading:20687982-Male,
pubmed-meshheading:20687982-Middle Aged,
pubmed-meshheading:20687982-Pregnadienediols,
pubmed-meshheading:20687982-Recovery of Function,
pubmed-meshheading:20687982-Respiratory Function Tests,
pubmed-meshheading:20687982-Treatment Outcome
|
pubmed:articleTitle |
Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids.
|
pubmed:affiliation |
Allergy and Asthma Specialists Medical Group, Huntington Beach, Californai 92647, USA. sfw@ocallergy.com
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|